Assessment of Mouth-Level Exposure to Tobacco Constituents in U.S. Snus Consumers

被引:10
作者
Caraway, John W. [1 ]
Chen, P. X. [1 ]
机构
[1] RJ Reynolds Tobacco Co, Res & Dev, Winston Salem, NC 27102 USA
关键词
N-NITROSAMINES; SWEDISH SNUS; CHEWING GUM; BETEL QUID; NICOTINE; SMOKING; SALIVA; CONSUMPTION; PRODUCTS; CHEWERS;
D O I
10.1093/ntr/nts187
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
When assessing the health risks associated with different tobacco product categories (e.g., combustible and noncombustible), it is important to understand exposure. Snus, a smokeless tobacco product with lower levels of most tobacco-related toxicants than cigarette smoke, has been recently introduced in the United States. The objective of this study was to evaluate the mouth-level exposure (MLE) to selected tobacco constituents from snus by adult consumers of Camel SNUS (CSNUS). For 7 days, 53 adult CSNUS consumers used their usual brand styles ad libitum, collecting their snus pouches after use. The collected pouches and unused product were analyzed for nicotine, N-nitrosonornicotine (NNN), 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), N-nitrosoanabasine (NAB), N-nitrosoanatabine (NAT), benzo[a]pyrene (B[a]P), arsenic, cadmium, chromium, lead, and nickel. MLE was estimated using the difference between the constituent amounts in the used and unused snus products. CSNUS consumption averaged 3.3 pouches/day or approximately 1.98g/day. Mean nicotine MLE was 2.8mg/pouch or 9.4mg/day. Mean MLE to total tobacco-specific nitrosamines (TSNAs: NNK, NNN, NAB, and NAT) was 171.5ng/pouch or 527.7ng/day. B[a]P MLE averaged 0.2ng/pouch or 0.68ng/day. This study is the first to report snus MLE under normal conditions of use in a group of adult, U.S. snus consumers. On average, approximately 60%90% of the amounts of nicotine, TSNAs, and B[a]P initially present in a snus pouch remained in the pouch after use by snus consumers in this study. The results from this study provide a preliminary assessment of exposure to constituents present in snus, which is potentially useful in risk assessment.
引用
收藏
页码:670 / 677
页数:8
相关论文
共 31 条
[1]   ORAL MUCOSAL CHANGES AND NICOTINE DISPOSITION IN USERS OF SWEDISH SMOKELESS TOBACCO PRODUCTS - A COMPARATIVE-STUDY [J].
ANDERSSON, G ;
BJORNBERG, G ;
CURVALL, M .
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 1994, 23 (04) :161-167
[2]  
[Anonymous], 2008, RES 2007 NAT SURV DR
[3]  
[Anonymous], 2004, HLTH CONS SMOK REP S
[4]   Receptivity to Taboka and Camel Snus in a US test market [J].
Biener, Lois ;
Bogen, Karen .
NICOTINE & TOBACCO RESEARCH, 2009, 11 (10) :1154-1159
[5]   Patterns and behaviors of snus consumption in Sweden [J].
Digard, Helena ;
Errington, Graham ;
Richter, Audrey ;
McAdam, Kevin .
NICOTINE & TOBACCO RESEARCH, 2009, 11 (10) :1175-1181
[6]   NICOTINE CONCENTRATIONS IN URINE AND SALIVA OF SMOKERS AND NONSMOKERS [J].
FEYERABEND, C ;
HIGENBOTTAM, T ;
RUSSELL, MAH .
BRITISH MEDICAL JOURNAL, 1982, 284 (6321) :1002-1004
[7]   Effect of smokeless tobacco (snus) on smoking and public health in Sweden [J].
Foulds, J ;
Ramstrom, L ;
Burke, M ;
Fagerström, K .
TOBACCO CONTROL, 2003, 12 (04) :349-359
[8]  
Fowler K. W., 2012, STANDARDIZATION PREP
[9]  
Health Canada, 1999, T309 HLTH CAN
[10]  
Health Canada, 1999, T306 HLTH CAN